Indeglitazar is primarily researched for its potential therapeutic applications in the management of metabolic disorders, particularly type 2 diabetes. It functions as a dual agonist of peroxisome proliferator-activated receptors (PPARs), specifically targeting PPAR-alpha and PPAR-gamma. This dual activation helps improve insulin sensitivity, regulate blood glucose levels, and enhance lipid metabolism. By modulating these pathways, it may reduce the risk of cardiovascular complications often associated with diabetes. Additionally, its effects on lipid profiles could make it a candidate for addressing dyslipidemia. However, its development has faced challenges, and further studies are required to fully understand its efficacy and safety profile in clinical settings.